Treatment of cerebral vasospasm with cilostazol in subarachnoid haemorrhage model

Acta Neurochirurgica, Supplementum

Volumn , Issue 104, 2008, Pages 291-295

  Bilginer, Burçak ^a   Oal B ^a   YigitkanlI K ^b   Soylemezoglu F ^a   Bavbek, M ^b   Ziyal, I M ^a   Ozgen T ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Social Security Hospital   (Turkey)

Author keywords

basilar artery; cerebral vasospasm; Cilostazol; subarachnoid haemorrhage

Indexed keywords

CILOSTAZOL; FIXATIVE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY PERFUSION; BASILAR ARTERY; BRAIN VASOSPASM; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; KRUSKAL WALLIS TEST; MOUSE; NONHUMAN; RABBIT; SUBARACHNOID HEMORRHAGE;

EID: 77953814754     PISSN: 00651419     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-75718-5_60     Document Type: Conference Paper

References (18)

1. Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S (2001) Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. Neurosurgery 48:723-730
2. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75:725-748
3. Biller J, Godersky JC, Adams HPJ (1988) Management of aneurysmal subarachnoid hemorrhage. Stroke 19:1300-1305
4. Birk S, Kruuse C, Petersen AK, Jonassen O, Hansen PT, Olesen J (2004) The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24:1352-1358
5. Choi JM, Shin HK, Kim KY, Lee JH, Hong KW (2002) Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J Pharmacol Exp Ther 300:787-793
6. Dorsch N (1995) Cerebral arterial spasm - a clinical review. Br J Neurosurg 9:403-412
7. Ecker A, Riemenschneider PA (1951) Arteriographic demonstration of spasm of the intracranial arteries. J Neurosurg 8:660-667
8. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18:1942-1947
9. Grasso G (2004) An overview of new pharmacological treatments for cerebrovascular dysfunction after experimental subarachnoid hemorrhage. Brain Res Rev 44:49-63
10. Ikeda Y (1999) Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 82:435-438
11. Inoue T, Sohma R, Morooka S (1999) Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro. Thromb Res 93:137-143
12. Mayberg M (2004) A clinical update on the diagnosis and treatment of subarachnoid hemorrhage. Focus on Medical Management, pp 5-11. Dannemiller Foundation, San Antonio, TX
13. Schrör K (2002) The pharmacology of cilostazol. Diabetes Obesity and Metabolism 4 (Suppl 2): S14-S19
14. Sobey CG (2001) Cerebrovascular dysfunction after subarachnoid hemorrhage: novel mechanisms and directions for therapy. Clin Exp Pharmacol Physiol 28:926-929
15. Sorkin EM, Markham A (1999) Cilostazol. Drugs Aging 14:63-71
16. Tamai Y, Takami H, Nakahata R, Ono F, Munakata A (1999) Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis 29:269-276
17. Weir B, Grace M, Hansen J, Rothberg C (1978) Time course of vasospasm in man. J Neurosurg 48:173-181
18. Wilkins RH (1990) Cerebral vasospasm. Crit Rev Neurobiol 6:51-76